Moderna shares fall despite promising data from cancer vaccine trial
Moderna’s mRNA vaccine, when combined with Merck’s blockbuster drug Keytruda, showed promise in treating melanoma, a kind of skin cancer.
Wells Fargo says this little-known biotech company could rally more than 80%
Analyst Derek Archila said shares of Viridian Therapeutics have more than 80% upside, citing a promising treatment for thyroid eye disease currently in trials.
Homebuilder sentiment rises in April, as builders grab near-record share of the market
Homebuilder sentiment rose in April, as builders gained an edge from a lack of supply on the resale market.
EU lawmakers call for a new set of rules for A.I. tools such as ChatGPT
The letter comes after prominent AI experts called on Europe to make its AI rules more expansive, arguing that excluding general purpose AI would miss the mark.
GM reveals Buick Envista as brand’s last new gas-powered vehicle
The 2024 Buick Envista will be the brand’s last new gas-powered vehicle ahead of its transition to an all-electric domestic lineup by 2030.
Piper Sandler says it’s bullish again on this solar energy stock
Piper Sandler upgraded shares of Enphase Energy to overweight, saying that the company’s U.S. business is not as bad as it has previously feared.
JPMorgan upgrades this tech stock ahead of a second half PC recovery
JPMorgan says HP could gain 17% by yearend as the PC industry rebounds later in 2023. The bank upgraded HP shares to overweight and raised its price target.
Volkswagen reveals the ID.7, new flagship EV with more than 300 miles of range
Volkswagen’s new ID.7 will serve as a flagship for the automaker’s growing line of mainstream EVs.
Piper Sandler says this biotech stock can outperform thanks to Alzheimer’s treatment
Piper Sandler says Alzheimer’s treatment Leqembi will help drive the stock up 20% in coming months. Leqembi is currently awaiting full approval from the FDA.
UBS says buy this ‘underappreciated’ software stock that can go up 35%
The bank initiated coverage on Okta with a buy rating and a price target of $100, which implies 35% upside from Friday’s closing price.
